Company news
Valirx Plc (LSE:VAL) news
Valirx Plc news releases on 6ix. Latest, May 29, 2020: Patent Assignment
Press releases — page 4
Patent Assignment
May 29, 2020
Proposed Board Change
May 27, 2020
Result of General Meeting
May 22, 2020
Group Projects Summary & Board Expansion Plans
May 19, 2020
Conditional Fundraise of £1.2 million
May 4, 2020
Share Price Movement
May 1, 2020
Change of Management Team
April 30, 2020
Statement re social media reports
April 29, 2020
Result of General Meeting & Directorate Change
April 14, 2020
Change of Arrangements for General Meeting
April 9, 2020
Conditional Placing
April 1, 2020
Update
March 30, 2020
General Meeting - Adjournment
March 25, 2020
Posting of Circular & Notice of General Meeting
March 16, 2020
Result of General Meeting & working capital update
February 17, 2020
Change of Venue for General Meeting-17 Feb 2020
February 12, 2020
Update - ValiSeek
January 14, 2020
Placing, Issue of Warrant & Appointment of Broker
January 6, 2020
VAL201 Update
December 16, 2019
US Patent Grant re VAL201 & Metastatic Cancer
November 28, 2019
Appointment of Joint Broker
November 13, 2019
Passing of Non-Executive Chairman
October 21, 2019
Placing & Issue of Equity
October 14, 2019
Company Update
September 24, 2019
Company Update & Change of Adviser
August 6, 2019
New European patent allowance for VAL301
August 1, 2019
Marketing and Communications Update
July 10, 2019
Change of Registered Address
July 9, 2019
Update re VAL301
July 4, 2019
US Notice of Allowance-VAL201 & Metastatic Cancer
June 26, 2019
Further re: Termination of Subscription Agreement
June 25, 2019
Update on VAL201 Clinical Trial
June 20, 2019
Placing, Subscription Agreement & Issue of Warrant
June 13, 2019
Subscription Agreement Update
June 10, 2019
Notice of AGM & Update of Subscription Agreement
June 5, 2019
Acquisition of Intellectual Property& JV Agreement
May 2, 2019
Subscription, Convertible Funds and Warrant Issue
April 26, 2019
Valirx (VAL): VAL401 is going forward
April 15, 2019
ValiSeek Update
March 26, 2019
Update on VAL201 & VAL301 Development Progress
March 21, 2019
Placing, Issue of Equity and Warrant
February 21, 2019
New patent grant allowances for VAL301
January 31, 2019
Publication of VAL401 peer-reviewed article
January 11, 2019
ValiRx endorses the Government's new NHS strategy
January 9, 2019
Issue of Equity / PDMR Shareholdings
December 18, 2018
Re scientific and investor meetings
November 5, 2018
ValiRx (VAL): VAL401 Phase II trial completed
November 1, 2018
Align Research Initiates Coverage
October 24, 2018
VAL201 in concluding stages of Phase I/II trial
October 17, 2018
VAL401 results shortly to be on ClinicalTrials.gov
October 15, 2018